Should a pooled analysis of FDA trials be considered representative for a population?
Crossref DOI link: https://doi.org/10.1111/opo.12884
Published Online: 2021-09-08
Published Print: 2021-11
Update policy: https://doi.org/10.1002/crossmark_policy
Kanclerz, Piotr
Masters, Jordan
Version of Record valid from 2021-09-08
Publication History
Published: 2021-09-08